Wenbin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenbin Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dan Tong
Changping Laboratory, Beijing, China
10 shared publications - Guohui Dang
Changping Laboratory, Beijing, China
10 shared publications - Jinyu Wang
Changping Laboratory, Beijing, China
10 shared publications - Lu Qi
Changping Laboratory, Beijing, China
10 shared publications - Sijin Cheng
Institute for Data-Driven Tumor Immunology, Chongqing Medical University, Chongqing 400016, China
10 shared publications - Tianyi Ma
Division of Life Sciences and Medicine, University of Science and Technology of China, hefei, China
10 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-18 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Supplementary Figure 1 Host p53 regulates cancer immunotherapy in melanoma model. Supplementary Figure 2 Analysis of tumor-infiltrating cells in response to PI immunotherapy. Supplementary Figure 3 Cd8+ T cells are essential for tumor suppression in response to PI immunotherapy. Supplementary Figure 4 Establishment of PDX-based immunotherapeutic model with humanized mouse. Supplementary Figure 5 Further analysis of T cell-intrinsic p53 CTD acetylation in response to immunotherapy. Supplementary Figure 6 Generation of the p53fl7KR/fl7KR cKI mouse model. Supplementary Figure 7 CTD acetylation of T cell-intrinsic p53 contributes to PI immunotherapy in melanoma model. Supplementary Figure 8 Generation and characterization of p53fl7KQ/fl7KQ cKI mouse model. Supplementary Figure 9 Functional analysis of tumor-infiltrating T cells in p53+/-, Lck-Cre and p53fl7KQ/-, Lck-Cre mice. Supplementary Figure 10 CTD acetylation-mimicking p53 in T cells regulates antitumor immunity in melanoma model. Supplementary Figure 11 The effect of PI immunotherapy in p53fl7KQ/-, Lck-Cre recipient mice. Supplementary Figure 12 Activation of T cell-intrinsic p53 slightly enhances T cell-mediated cytotoxicity. Supplementary Figure 13 scRNA-seq analysis of tumor-infiltrating lymphocytes. Supplementary Figure 14 Functional analysis of Ccl5 in T cell-intrinsic p53-mediated antitumor immunity. Supplementary Figure 15 Activation of the IFN-γ pathway promotes Ccl5 transcriptional expression in Cd8+ T cells. Supplementary Figure 16 Further analysis of the crosstalk between p53 CTD acetylation and IFN-γ. Supplementary Figure 17 Mechanistic details of VPRBP-mediated repression of p53-dependent Ifng transcription. Supplementary Figure 18 Further analysis of IFN-γ/JAK-STAT pathways regulated by p53 CTD acetylation in Cd8+ T cells.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
Although p53 plays a central role in tumor suppression, how it is regulated in T cells to exert antitumor effects remains unclear. In this study, we show that activation of T cell–intrinsic p53 via carboxyl-terminal domain (CTD) acetylation during immunotherapy activates the IFN-γ pathway, promotes CD8+ T-cell infiltration, and elicits CD8+ T cell–dependent antitumor immunity. Using T cell–specific knockin mouse models, we demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell–dependent antitumor immunity whereas expression of CTD acetylation–mimicking p53 in T cells enhances this immune response. Moreover, we identify IFNG as a direct target of T cell–intrinsic p53 and uncover a positive feedback loop between p53 and the IFN-γ pathway for enhancing T cell–dependent antitumor immunity. Our study reveals that CTD acetylation–mediated activation of T cell–intrinsic p53 promotes antitumor immunity in response to immunotherapy, highlighting a non–tumor cell–autonomous mechanism of p53 action by regulating adoptive immune responses.Significance:This study identifies T cell–intrinsic p53 as a key determinant of immunotherapy efficacy. CTD acetylation, rather than stabilization, activates a p53–IFN-γ feedback loop and promotes CD8+ T cell–mediated antitumor immunity independently of tumor p53 status. These findings reveal a non–tumor cell–autonomous action of p53 to boost PD-1–based immunotherapy.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Source Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSource Data 1 from Activation of T Cell–Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy
This file contains the raw data of this study.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S1. Dataset statistics and annotation workflow, related to Figure 1.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S1. Dataset statistics and annotation workflow, related to Figure 1.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S2. Transcriptional characteristics of different DC subsets, related to Figure 1.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S2. Transcriptional characteristics of different DC subsets, related to Figure 1.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S5. Characteristics of LAMP3+ DC and performance of our prediction model, related to Figures 5 and 6.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S5. Characteristics of LAMP3+ DC and performance of our prediction model, related to Figures 5 and 6.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S3. Characteristics and tissue distribution of cDC2 subsets, related to Figure 2.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S3. Characteristics and tissue distribution of cDC2 subsets, related to Figure 2.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S4. Characteristics of AS DC and LC-like subsets, related to Figures 3 and 4.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S4. Characteristics of AS DC and LC-like subsets, related to Figures 3 and 4.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S6. Performance of our prediction model, related to Figure 6.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S6. Performance of our prediction model, related to Figure 6.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S7. Dissecting the heterogeneity of cDC1s, related to Discussion.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
Supplementary Figure S7. Dissecting the heterogeneity of cDC1s, related to Discussion.